Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
The Print on MSN
Budget cuts import costs of 17 cancer & 7 rare disease drugs. Why it offers little relief to patients
Cancer imposes catastrophic health expenditure in India, with medicines constituting over 60% of out-of-pocket expenditure.
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® ...
Trastuzumab and T-DXd are effective in HER2-positive gastric and GEJ cancers, moving towards earlier intervention stages. A meta-analysis of T-DXd showed significant efficacy and manageable safety in ...
HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...
The move can significantly lower out‑of‑pocket burdens for families, given that India’s health insurance coverage for ...
At the San Antonio Breast Cancer Symposium (SABCS), investigators outlined the rationale and design of the ERADICATE, a first-in-human study evaluating the combination of the oral selective estrogen ...
Daiichi Sankyo & AstraZeneca’s Enhertu approved in China as first and only HER2 directed ADC for second-line treatment of patients with HER2 positive metastatic gastric cancer ...
Beyond drugs and manufacturing, the Union Budget 2026-27 proposes significant structural upgrades to India's healthcare ...
At the San Antonio Breast Cancer Symposium, researchers discussed how results from HER2CLIMB-05 may inform first-line ...
The EMA validation of T-DXd with pertuzumab could change the standard of care for HER2-positive metastatic breast cancer in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results